Pular para o conteúdo principal
Ranking Invest

ALDX - Aldeyra Therapeutics, Inc.

Segmento: HealthcareAldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Análise Ranking Invest

Valuation estimado
-9,46%
-$ 109.45 Mi
Valor de Mercado
$ 80.84 Mi
Desconto (AV)-173.9%
IVR
-1.35A companhia vale -1,35 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-1.82O valuation alternativo equivale a -182% do valor de mercado da companhia.
MLL
-1.82O lucro líquido dos controladores em 16 trimestres equivale a -182% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 37.89 Mi

L4T

-$ 23.05 Mi

Indicadores Básicos

ROE

-60.85%

Índices de Previsibilidade

Receita Líquida

G1.82

Lucro

C0.29

Margem

E1.69

Índices de Tendência

Receita Líquida

D0.79

Lucro

B5.93

Margem

C1.58

Índices de Endividamento

DIV/PAT

0.00

DIV/L4T

0.00

Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.